Oral EV supplements: the DSHEA route in the US, the novel-food route in the EU

Swallow an EV product instead of applying it, and cosmetics law stops applying — food law takes over. Two frameworks matter, and both reward the same thing — a documented material.

US: the DSHEA frame

Dietary supplements under DSHEA are products intended to supplement the diet, labeled with structure/function-style discipline and the standard disclaimer: not intended to diagnose, treat, cure or prevent any disease. What DSHEA rewards is exactly what a documented EV chain provides — ingredient identity, manufacturing records, safety substantiation. What it punishes is disease claims dressed as wellness language. A quick-dissolve tablet can compete on format and ritual; its claims must come from the dossier, not the label.

EU: food supplement and novel food

The EU routes oral formats through the food-supplement framework, with novel-food assessment where an ingredient's consumption history requires it — a hard gate for a new material class — and the reason EU oral launches need a longer runway. Budget the assessment into your launch calendar. Permitted-claims lists govern what the pack can say; member-state enforcement of borderline claims is active.

Why the documentation chain decides

Both frameworks turn on the same question regulators and retail buyers ask: what exactly is this ingredient, and can you prove it? A material line holding FDA DMF Type II and INCI documentation, with batch COAs and a characterization baseline, answers the question before a buyer asks it. Published human evidence for oral EV delivery — encapsulation improving a polyphenol's bioavailability over a two-week intervention — supports the design logic as background, not as product claim.

The TriSleep™ oral playbook carries the full route design — or bring your market and format for a route check.